• 

  An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. 

  Jepson, Marcus; Elliott, Daisy; Conefrey, Carmel; Wade, Julia; Rooshenas, Leila; Wilson, Caroline; Beard, DavidBlazeby, Jane MBirtle, AlisonHalliday, AlisonStein, RobDonovan, Jenny LCSAW study group,Chemorad study group,POUT study group,ACST-2 study group,OPTIMA prelim study group, et al. (2018-07)

  © 2018 University of Bristol Objectives: To explore how the concept of randomization is described by clinicians and understood by patients in randomized controlled trials (RCTs) and how it contributes to patient understanding ...
• 

  Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling 

  Periasamy, Jayaprakash; Kurdekar, Vadiraj; Jasti, Subbarao; Nijaguna, Mamatha B; Boggaram, Sanjana; Hurakadli, Manjunath A; Raina, DhruvKurup, Lokavya MeenakshiChintha, ChetanManjunath, KavyashreeGoyal, AneeshSadasivam, GayathriBharatham, KavithaPadigaru, MuralidharaPotluri, VijayVenkitaraman, Ashok et al. (Elsevier, 2018-06)

  Intracellular signals triggered by DNA breakage flow through proteins containing BRCT (BRCA1 carboxyl-terminal) domains. This family, comprising 23 conserved phosphopeptide-binding modules in man, is inaccessible to ...
• 

  A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer. 

  Hamilton, Erika P; Patel, Manish R; Armstrong, Anne C; Baird, Richard; Jhaveri, Komal; Hoch, Matthias; Klinowska, TeresaLindemann, Justin POMorgan, Shethah RSchiavon, GaiaWeir, Hazel MIm, Seock-Ah et al. (American Association for Cancer Research, 2018-02-13)

  Purpose: AZD9496 is an oral nonsteroidal, small-molecule inhibitor of estrogen receptor alpha (ERα) and a potent and selective antagonist and degrader of ERα. This first-in-human phase I study determined the safety and ...
• 

  The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. 

  Weigelt, Britta; Bi, Rui; Kumar, Rahul; Blecua, Pedro; Mandelker, Diana L; Geyer, Felipe C; Pareja, FresiaJames, Paul AkConFab Investigators,Couch, Fergus JEccles, Diana MBlows, FionaPharoah, PaulLi, AnqiSelenica, PierLim, Raymond SJayakumaran, GowthamWaddell, NicShen, RonglaiNorton, LarryWen, Hannah YPowell, Simon NRiaz, NadeemRobson, Mark EReis-Filho, Jorge SChenevix-Trench, Georgia et al. (OUP, 2018-02-28)

  Pathogenic germline variants in ataxia-telangiectasia mutated (ATM), a gene that plays a role in DNA damage response and cell cycle checkpoints, confer an increased breast cancer (BC) risk. Here, we investigated the ...

View more